| Revenue growth | 27% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA Margin at 34.7%; PAT Margin improved to 25.6%. |
| Demand visibility | Strong customer engagement and increasing visibility on battery material off-take. |
| Management confidence | High; confident in sustainable long-term growth and expansion projects. |
Growth
Q1FY27 Revenue grew 27% YoY to ₹158.3 Cr; PAT rose 30% YoY to ₹40.6 Cr.
Outlook
Greenfield expansion and SAM Phase 1 on track for March 2027; total capacity targeted at 2,28,700 MT by FY30.
Risks
Challenging global environment, geopolitical uncertainties, supply chain disruptions, gas constraints, and elevated logistics costs.
Last quarter's promises, checked
Delivered
- Guided 25,000 MT Phase 1 SAM commissioning by April 2027 → On track for March 2027 (= BEAT)
- Guided 150-160 working capital days → delivered 154 days (= BEAT)
- Guided 10% revenue growth for Pharma/Food segment → delivered 10% (= BEAT)
Partly delivered
- Guided EBITDA margins returning to 37-38% → delivered 34.7% (= PARTIAL)
Investor Presentation filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹13,271 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.7×Sector 47.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Other Announcement
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Annual General Meeting
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Sudeep Pharma Capital Structure Change
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.